Status:
COMPLETED
Age-Related Eye Disease Study 2 (AREDS2)
Lead Sponsor:
National Eye Institute (NEI)
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Office of Dietary Supplements (ODS)
Conditions:
Age-related Macular Degeneration
Cataract
Eligibility:
All Genders
50-85 years
Phase:
PHASE3
Brief Summary
Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age...
Detailed Description
AREDS2 was a randomized, double-masked, placebo-controlled, 2x2 factorial trial evaluating the risks and benefits of adding lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), or both to ...
Eligibility Criteria
Inclusion
- Men and women between the ages of 50 and 85 years
- Macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye
Exclusion
- Ocular media not clear enough to allow good fundus photography
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
4203 Patients enrolled
Trial Details
Trial ID
NCT00345176
Start Date
September 1 2006
End Date
October 1 2012
Last Update
May 5 2015
Active Locations (91)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
Jones Eye Institute - UAMS
Little Rock, Arkansas, United States, 72205
3
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
4
Shiley Eye Center - UCSD
La Jolla, California, United States, 92093